Resumen de New clinical trials regulation in Spain: analysis of royal decree 1090/2015
Miguel Martín Jiménez, Aitana Calvo Ferrándiz, Jorge Aparicio Urtasun, María Rosario García Campelo, E. González Flores, Martin Lázaro Quintela, Montserrat Muñoz, César Augusto Rodríguez Sánchez, Ana Santaballa Bertrán, Juan Manuel Sepúlveda Sánchez, Ruth Vera García, Juan Antonio Virizuela Echaburu, Miguel Ángel Seguí Palmer
The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratization, and thus, it became evident that procedures needed to be simplified without detriment to patient’s safety. Thus, Regulation 536/2014, that repealed Directive 2001/20/EC, with the aim of decreasing the growing bureaucratization and stimulating clinical research in Europe, established simplified procedures, such as regulating a common procedure for authorising trials in Europe, the institution of strict assessment timelines, or the definition of new concepts, such as “low-intervention clinical trial”. The legal form of a Regulation allowed the norm to be directly applied to Member States without the need for transposition. By means of the new Royal Decree, the national legislation is adapted to make the application of the regulation feasible and it allows the development of the aspects that the Regulation leaves to national legislation. Both documents seek to stimulate clinical research with medicinal products to foster knowledge, facilitate transparency, and reinforce subjects’ safety. This will surely be the case, but with this revision, we will look at the novelties and key aspects that are most relevant to investigators and we will analyse the consequences for all parties involved in clinical research.
